Clinical trials: Neck Cancer
Uterine Cervical Neoplasms
Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer
BVAC-C is an immunotherapeutic vaccine using B-Cell and Monocytes as antigen-presenting cells. This study is consists of 2 parts. Phase I is for safety evaluation, and Phase IIa is for efficacy assessment.
- Trial name
- NCT02866006
- Testing
- BVAC-C, Topotecan
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Cellid Co., Ltd.
Oral Mucositis
Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects
The purpose of this study is to evaluate the safety and efficacy of ALD518 in modifying the course of oral mucositis in subjects with head and neck cancer receiving concomitant chemotherapy and radiotherapy
- Trial name
- NCT01403064
- Testing
- ALD518, 0.9% saline
- Where
- 31 sites in United States, Australia and 4 more
- Volunteers
- 76 people
- Sponsor
- CSL Behring
Advanced Solid Tumor, Unresectable Solid Tumor
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Colorectal Adenocarcinoma
- Trial name
- GUARDIAN-101 (NCT06778863)
- Testing
- CLSP-1025
- Where
- 21 sites in United States
- Volunteers
- 90 people
- Sponsor
- Clasp Therapeutics, Inc.
Neoplasms, Head and Neck
Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck
This study is being conducted to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in adult subjects with squamous cell carcinoma of the head and neck (SCCHN).
- Trial name
- NCT00725764
- Testing
- GSK1363089 (foretinib)
- Where
- 11 sites in United States
- Volunteers
- 14 people
- Sponsor
- GlaxoSmithKline
Head and Neck Squamous Cell Carcinoma
Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck (IL12HNSCC)
This study will assess the safety and effectiveness of ImmunoPulse IL-12® in treatment-refractory metastatic and unresectable squamous cell carcinoma of the head and neck (HNSCC).
- Trial name
- NCT02345330
- Testing
- Tavokinogene Telseplasmid (tavo), OncoSec Medical System (OMS)
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- OncoSec Medical Incorporated
Ovarian Serous Adenocarcinoma, Undifferentiated Carcinoma of Ovary
Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity
This study is a clinical study aiming at establishing immunological assays for the qualitative and quantitative evaluation of WT-1, Survivin and HPV16 E7-specific immune responses in cancer patients.
- Conditions
- Ovarian Serous Adenocarcinoma, Undifferentiated Carcinoma of Ovary, Cervical Cancer, Cervical Intraepithelial Neoplasia, Grade 3
- Trial name
- NCT02016833
- Testing
- Blood Sampling
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- PX Biosolutions
Lumbar Spinal Stenosis, Spondylolisthesis, Grade 1
Pedicle Osteotomy for Stenosis Trial
This is a pivotal Randomized Clinical trial to compare the safety and effectiveness of the Pedicle Lengthening Osteotomy Procedure with implantation of the Altum® Device to open surgical decompression and Transforaminal Lumbar…
- Conditions
- Lumbar Spinal Stenosis, Spondylolisthesis, Grade 1, Neurogenic Claudication
- Trial name
- POST (NCT03381677)
- Testing
- Pedicle Lengthening Osteotomy with Altum® Device, Control
- Where
- United States
- Volunteers
- 344 people
- Sponsor
- Innovative Surgical Designs
Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
The purpose of this first in human (FIH) trial was to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and identify a recommended dose for future studies in…
- Conditions
- Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal Squamous Cell Cancer (SCC), Head/Neck SCC
- Trial name
- NCT03114319
- Testing
- TNO155, TNO155 in combination with EGF816 (nazartinib)
- Where
- 18 sites in United States, Canada and 7 more
- Volunteers
- 227 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumours, Non-Small Cell Lung Cancer
First in Human Study of SIM0610 in Solid Tumors
This is a multicenter, open-label, first-in-human (FIH) study to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic profile, and preliminary antitumor activity of SIM0610 in subjects with locally…
- Conditions
- Advanced Solid Tumours, Non-Small Cell Lung Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- SIM0610-101 (NCT07348211)
- Testing
- SIM0610 for Injection
- Where
- 7 sites in China
- Volunteers
- 260 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Cervical Cancer, Anal Cancer
CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers
A single center, open, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of CRTE7A2-01 TCR-T cell for HPV16 positive advanced cervical, anal, or head and neck cancers.
- Conditions
- Cervical Cancer, Anal Cancer, Head and Neck Cancers
- Trial name
- NCT05122221
- Testing
- Fludarabine + Cyclophosphamide, Interleukin-2, CRTE7A2-01 TCR-T Cell
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Corregene Biotechnology Co., Ltd
Head and Neck Cancer, Lung Cancer
Study of [F 18]HX4 Positron Emission Tomography (PET) as a Tool to Detect Hypoxia in Tumors
This pilot phase II study is designed as a test and retest study to investigate [F 18]HX4 as a reliable non-invasive PET imaging marker for detection of tumor hypoxia regions and to establish a threshold for [F 18]HX4 uptake in…
- Conditions
- Head and Neck Cancer, Lung Cancer, Liver Cancer, Rectal Cancer
- Trial name
- HX4-200 (NCT01075399)
- Testing
- [F 18]HX4
- Volunteers
- 50 people
- Sponsor
- Siemens Molecular Imaging
Head and Neck Neoplasms
E10A for the Treatment of Squamous Cell Carcinoma of the Head and Neck
Recombinant human endostatin adenovirus injection is a novel anti-tumor gene therapy drug. E10A contains a recombinant human endostatin gene with the second-generation recombinant adenovirus as its vector.
- Trial name
- NCT02630264
- Testing
- Endostatins, Paclitaxel injection, Cisplatin injection
- Where
- China
- Volunteers
- 540 people
- Sponsor
- Guangzhou Double Bioproducts Co., Ltd
Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
The purpose of this study is to learn about the effects of a new study medicine called PF-08046032, when taken alone and when taken with another medicine called sasanlimab, for the treatment of advanced cancers.
- Conditions
- Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma, Classical Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT06870487
- Testing
- PF-08046032, Sasanlimab
- Where
- 4 sites in United States, Spain
- Volunteers
- 6 people
- Sponsor
- Pfizer
Advanced Solid Tumor, PDAC
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conjugate which may be used in the future as a possible treatment for…
- Conditions
- Advanced Solid Tumor, PDAC, HNSCC
- Trial name
- NCT06597721
- Testing
- ADCE-T02
- Where
- 14 sites in United States, Australia
- Volunteers
- 210 people
- Sponsor
- Adcendo ApS
Nasopharyngeal Carcinoma
A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects
This is an open-label, single center, non-randomized, phase I trial to evaluate safety and efficacy of using the combination treatment of SHR-1210, gemcitabine and cis-platinum by recurrent and metastatic NPC.
- Trial name
- NCT03121716
- Testing
- SHR-1210, Gemcitabine, cis-platinum
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Infections, Papillomavirus
A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years
Human papillomavirus infection has clearly been recognized as the cause of cervical cancer. The infection of the cervix by certain oncogenic types of HPV, if not cleared, can lead to cervical cancer in women.
- Trial name
- NCT00485732
- Testing
- HPV-16/18 VLP/AS04 vaccine (Cervarix TM)
- Where
- 6 sites in South Korea
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cancer of Head and Neck, Lung Cancer, Nonsmall Cell
A Multicenter Cancer Biospecimen Collection Study
This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor…
- Conditions
- Cancer of Head and Neck, Lung Cancer, Nonsmall Cell, Small-cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NCT04510129
- Testing
- OncoPrism™ assay
- Where
- United States
- Volunteers
- 1,650 people
- Sponsor
- Cofactor Genomics, Inc.
Cervical Cancer
A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01
This is a seamless Phase 1/2 study consisting of two components. Phase 1 component is a dose-escalation, single arm, open label study in 10 patients to evaluate the safety and tolerability of KRC 01.
- Trial name
- NCT05570422
- Testing
- KRC-01, External Beam Radiation Therapy, cisplatin
- Where
- 4 sites in India, Thailand and 1 more
- Volunteers
- 70 people
- Sponsor
- Kortuc, Inc.
Recurrent or Metastatic Cervical Cancer
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
This study is a multicentre, open-label, dose-finding/efficacy-expanding phase Ib/II clinical trial to evaluate the tolerability, safety, pharmacokinetic profile and immunogenicity of SHR-A1811 combination regimen in the…
- Trial name
- NCT06859775
- Testing
- SHR-A1811, Adebelimab injection, Bevacizumab injection
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer
This was a Phase 2a trial to investigate the safety and biological activity of the RIX-2 Regimen in patients with untreated, resectable squamous cell cancer of the head and neck (HNSCC).
- Trial name
- NCT00210470
- Testing
- IRX-2, Cyclophosphamide, Indomethacin
- Volunteers
- 27 people
- Sponsor
- Brooklyn ImmunoTherapeutics, LLC